Potential conflict of interest: Nothing to report.
Autoimmune hepatitis in childhood
Article first published online: 10 FEB 2014
© 2013 by the American Association for the Study of Liver Diseases
Clinical Liver Disease
Special Issue: Autoimmune Liver Disease, Part 1
Volume 3, Issue 1, pages 6–8, January 2014
How to Cite
Mieli-Vergani, G. and Vergani, D. (2014), Autoimmune hepatitis in childhood. Clinical Liver Disease, 3: 6–8. doi: 10.1002/cld.296
- Issue published online: 10 FEB 2014
- Article first published online: 10 FEB 2014
Watch a video presentation of this article
Watch the interview with the author
antibody to liver cytosol type 1
antibody to liver kidney microsomal type 1
antibody to soluble liver antigen
autoimmune sclerosing cholangitis
endoscopic retrograde cholangiopancreatography
inflammatory bowel disease
immunofluorescence on rodent tissue
magnetic resonance cholangiopancreatography
peripheral anti–nuclear neutrophil antibody
smooth muscle antibody.
Autoimmune hepatitis (AIH) is characterized histologically by interface hepatitis, biochemically by increased transaminase levels, and serologically by circulating autoantibodies and high immunoglobulin G (IgG) levels.
Clinical Features (Table 1)
There are two forms of juvenile AIH: type 1 (AIH1), which is positive for smooth muscle antibodies (SMAs) and/or anti-nuclear antibodies (ANAs), and type 2 (AIH2), which is positive for antibody to liver kidney microsomal type 1 (anti-LKM1) and/or antibody to liver cytosol type 1 (anti-LC1). In both forms, approximately 80% of the patients are girls.
|Median age (years)||11||7||12|
|Mode of presentation (%)|
|Fulminant hepatic failure||3||25||0|
|Complication of chronic liver disease||12||10||26|
|Associated immune diseases (%)||22||20||48|
|Family history of autoimmune disease (%)||43||40||37|
|Bile duct changes on cholangiography (%)||0||0||100|
|Increased IgG level (%)||84||75||89|
|Partial IgA deficiency (%)||9||45||5|
In children/adolescents, a form of sclerosing cholangitis characterized by ANA and SMA positivity, high levels of IgG, and interface hepatitis [autoimmune sclerosing cholangitis (ASC)] is as prevalent as AIH1. In the absence of bile duct imaging, these patients are diagnosed with AIH1. ASC is often associated with inflammatory bowel disease (IBD) and affects boys and girls equally.
Other autoantibodies of diagnostic importance are peripheral anti–nuclear neutrophil antibodies (atypical peripheral anti–nuclear cytoplasmic antibodies or pANNAs) and antibody to soluble liver antigen (anti-SLA). pANNAs are frequent in AIH1 and ASC. Anti-SLA is found in 40% to 60% of AIH1, AIH2, and ASC patients and indicates a more severe course.
AIH1 accounts for two-thirds of cases and often presents around puberty, whereas AIH2 affects younger children, including infants. IgG levels are usually raised, but 16% of AIH1 patients and 25% of AIH2 patients have normal levels. Immunoglobulin A (IgA) deficiency is common in AIH2 patients.
There are three clinical patterns of AIH presentation: an acute pattern (rarely fulminant, particularly in AIH2) in approximately 50%, an insidious pattern (progressive fatigue, relapsing jaundice, headache, anorexia, and amenorrhea) in approximately 50%, and complications of portal hypertension (splenomegaly and bleeding varices) in approximately 10%. Hence, autoimmune liver disease should be excluded for all children with symptoms/signs of liver disease not ascribable to known pathologies.
AIH2 can be part of the autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy syndrome: the liver disease is present in approximately 20% of cases.
The diagnosis of AIH is based on inclusion and exclusion criteria established by the International Autoimmune Hepatitis Group for adult patients.[5, 6] The International Autoimmune Hepatitis Group scoring system is not suitable for juvenile AIH because diagnostically relevant autoantibodies often have titers lower than those considered positive in adults and because it does not allow a distinction to be made between AIH and ASC; this distinction can be made only with cholangiography (Table 2).
|Elevated transaminase levels|
|Exclusion of viral hepatitis, Wilson's disease, and nonalcoholic steatohepatitis|
|Positive for autoantibodies|
|ANA/SMA (IF titer ≥ 1:20)||AIH1 or ASC|
|Anti-LKM1 (IF titer ≥ 1:10) and/or anti-LC1||AIH2|
|Anti-SLA (enzyme-linked immunosorbent assay)||AIH1, AIH2, ASC|
|Elevated IgG levels|
|Cholangiogram (MRCP or ERCP)|
AIH responds well to immunosuppression, even in the presence of poor synthetic function and/or established cirrhosis. Prednisolone is started at 2 mg/g/day (maximum = 60 mg/day) and is gradually decreased over the course of 4 to 8 weeks in parallel with progressive normalization of transaminase levels to reach the minimal maintenance dose (usually 5 mg/day) able to sustain normal transaminase levels. During the first 6 to 8 weeks, liver function tests are checked weekly to fine-tune the treatment and avoid severe side effects. The initial goal is to obtain an 80% reduction of the baseline transaminase levels within 8 weeks of treatment. If progressive normalization of transaminases is not observed, azathioprine is added at a starting dose of 0.5 mg/kg/day; in the absence of toxicity, this is increased up to a maximum of 2 to 2.5 mg/kg/day until remission (i.e., normal transaminase levels). Azathioprine is not recommended as a first-line treatment because of its potential hepatotoxicity, particularly in severely jaundiced patients. Transaminase normalization may take several months.
Relapse on treatment affects approximately 40% and requires a temporary increase in the steroid dose. Often, relapse is due to nonadherence, particularly in adolescents. The risk of relapse is higher if steroids are administered on alternate days. Small daily doses are more effective at maintaining disease control and preventing the need for high-dose steroid pulses during relapses, and they do not ultimately affect growth.
Treatment is recommended for at least 3 years before cessation is considered. Treatment withdrawal can then be attempted if liver function tests and IgG levels have been persistently normal, autoantibodies have been either undetectable or detectable at very low titers (ANA/SMA < 1:10; negative findings for anti-LKM1) for at least 12 months, and a liver biopsy sample shows no inflammatory changes. Treatment withdrawal is successful in approximately 20% of AIH1 patients, but this is rare for AIH2 patients. Autoantibody titers and IgG levels correlate with disease activity. The prognosis for juvenile AIH is good; most patients survive a long time with excellent quality of life on low-dose medication. End-stage liver disease requiring liver transplantation (LT) despite treatment, however, develops in approximately 9% of patients within 15 years of the diagnosis.
The induction of remission has been reported with cyclosporine A alone for 6 months followed by maintenance with low-dose prednisone and azathioprine, but whether this is better than the standard treatment awaits an evaluation in controlled studies.
The induction of remission with the doses of budesonide used in adults has been disappointing in juvenile AIH, with a low remission rate after 12 months of treatment. Large controlled studies are needed to establish appropriate doses for children.
In the 10% of patients who do not respond to standard immunosuppression or are intolerant of azathioprine, mycophenolate mofetil (20 mg/kg twice daily) has been successfully used. In cases of persistent nonresponse, a calcineurin inhibitor (cyclosporine A or tacrolimus) should be considered.
In ASC, with early treatment, parenchymal liver damage responds well to the same immunosuppressive schedule used for AIH; ursodeoxycholic acid (15-20 mg/kg/day) is usually added, and there is good medium-/long-term survival. However, the bile duct disease progresses in approximately 50% of patients, and this leads to LT in approximately 20%. The progression of liver disease is associated with poorly controlled IBD.
LT is indicated for AIH patients with fulminant hepatic failure (with encephalopathy) and for AIH patients (approximately 10%) and ASC patients (approximately 23%) who develop end-stage liver disease despite treatment (Table 3). After LT, the reported recurrence rates are approximately 20% for AIH and 27% to 67% for ASC. AIH recurrence does not affect post-LT outcomes, whereas ASC recurrence, which is often associated with uncontrolled IBD, leads to retransplantation in a high proportion of patients.
|Remission rate (%)||97||87||89|
|Median time to remission (months)||6||9||2|
|Relapse rate (%)||42||46||45|
|Cessation of treatment (%)||19||0||5|
|LT rate (%)||6a||13a||23|
|Disease recurrence after transplantation (%)||0||0||67|
De Novo AIH After LT
AIH can arise de novo after LT in children not undergoing transplantation for autoimmune disease, and it is characterized by interface hepatitis (Fig. 1), high IgG levels, and positive findings for autoantibodies (ANAs, SMAs, and classic and atypical anti-LKM1). The same schedule of prednisolone and azathioprine used for classic AIH is highly effective and leads to excellent graft/patient survival, whereas the standard antirejection treatment fails; this makes an early diagnosis essential for preventing graft loss. Rapamycin is reportedly effective in difficult-to-treat patients.
- 7Therapeutic aspects of autoimmune liver disease in children. In: Dienes HP, Leuschner U, Lohse AW, Manns MP, eds. Autoimmune Liver Diseases. Dordrecht, the Netherlands: Springer; 2005:278-282. Falk Symposium 142., , , .
- 10Liver transplantation and autoimmune liver diseases. Liver Transpl 2013;19:1065-1077., , , .